Medicinal Products

Lemtrada

The medicinal product has been authorised by the European Commission (EC) via centralised procedure in all EU Member States, based on the European Medicines Agency (EMA) experts' opinion.

Name Lemtrada
Active Substance alemtuzumab
Prescription na recept
Type of prescription ograničeni recept
Distribution u ljekarni
ATC Code L04AA34
Medicinal product marketed in the Croatia Da
Summary of product characteristics (SmPC), labelling and package leaflet (PL) download
Link to the European Medicines Agency's (EMA) product information download
Link to the European Commission's (EC) decisions download
Educational materials
for healthcare professionals
Vodič za zdravstvene radnike, verzija 5
Kontrolni popis za liječnike, verzija 3
Educational materials
for patients / caregivers
Vodič za bolesnike, verzija 5
Kartica za bolesnike, verzija 5

Direct Healthcare Professional Communication

Name Date Download
Pismo zdravstvenim radnicima o ograničenju primjene lijeka Lemtrada zbog ozbiljnih nuspojava 18.04.2019 sanofi-aventis Croatia d.o.o.
Pismo zdravstvenim radnicima o ograničenju indikacije, dodatnim kontraindikacijama i mjerama minimizacije rizika za lijek Lemtrada (alemtuzumab) 23.01.2020 sanofi-aventis Croatia d.o.o.
Back